In May 2026, the strategic use of Oncolytic Viruses has emerged as one of the most innovative frontiers in cancer treatment. These genetically engineered viruses are designed to selectively infect and destroy cancer cells while simultaneously stimulating a robust immune response against the tumor.

At Onco Medicine, we are facilitating access to these complex "living therapeutics," which represent a unique synergy between virology and oncology.

The Dual-Action Mechanism

Oncolytic viruses offer a two-pronged attack against malignancies:

• Direct Lysis: The virus enters the cancer cell, replicates aggressively, and causes the cell to burst (lyse), directly reducing the tumor burden.
• Systemic Immune Activation: The destruction of the cancer cell releases tumor-specific antigens, alerting the immune system and turning a "cold" tumor into a "hot" one that is vulnerable to further immune attack.

Turning nature's microscopic invaders into cancer-fighting allies. This approach not only provides targeted destruction but also paves the way for highly effective combination therapies with checkpoint inhibitors. Onco Medicine is proud to be part of the network delivering these cutting-edge virotherapies to patients worldwide.